Estrogen receptor alpha 36 (ER-alpha36)

Estrogen receptor alpha 36 (ER-alpha36) is a 36-kDa splice variant of the classical 66-kDa estrogen receptor alpha (ER-alpha66). Unlike the full-length receptor, ER-alpha36 lacks both the AF-1 and AF-2 transactivation domains but retains the DNA-binding and ligand-binding domains, allowing it to function as a dominant-negative regulator of genomic estrogen signaling (1, 6). It is primarily localized to the plasma membrane and cytoplasm, where it mediates rapid, membrane-initiated non-genomic signaling pathways, including the MAPK/ERK and PI3K/Akt cascades (2, 5). ER-alpha36 plays a critical role in the progression of various malignancies, most notably breast cancer, where its high expression is strongly associated with aggressive phenotypes and resistance to endocrine therapies (1, 11). Interestingly, tamoxifen, which typically acts as an antagonist for the classical ER-alpha66, can act as an agonist for ER-alpha36, thereby promoting tumor growth in resistant cells (5, 9). Consequently, ER-alpha36 is a significant therapeutic target and biomarker for identifying patients likely to fail standard hormonal treatments (10, 15).

Other names

hER-alpha36ER-alpha variant 3636-kDa variant of estrogen receptor-alphaESR1 variant 36ERα36

ER-alpha36 mediates rapid, membrane-initiated non-genomic signaling by activating kinase cascades such as MAPK/ERK and PI3K/Akt upon ligand binding. It lacks intrinsic transcriptional activity due to the absence of AF-1 and AF-2 domains but competes with the full-length ER-alpha66 for DNA binding and sequesters estrogenic ligands, thereby inhibiting classical genomic signaling. In cancer cells, it often forms a positive feedback loop with growth factor receptors like EGFR and HER2 to drive mitogenic signaling and promote drug resistance.